Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). - Wikidata - wikimedia - TriplyDB

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

http://www.wikidata.org/entity/Q33909851

about

Q57692513 Q57692664

sameAs

Ketogenic diet in neuromuscular and neurodegenerative diseases Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease Opposite Interplay between PPAR Gamma and Canonical Wnt/Beta-Catenin Pathway in Amyotrophic Lateral Sclerosis Checkpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous System Riluzole for motor neurone disease. Reply from chairman of appraisal committee at NICE Metal-deficient aggregates and diminished copper found in cells expressing SOD1 mutations that cause ALS.ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?Amyotrophic lateral sclerosis: update for family physicians Outcomes of physical therapy, speech pathology, and occupational therapy for people with motor neuron disease: a systematic review.FTD and ALS: a tale of two diseases Dysphagia in Amyotrophic Lateral Sclerosis: Impact on Patient Behavior, Diet Adaptation, and Riluzole Management High-fat and ketogenic diets in amyotrophic lateral sclerosis.Factors predicting survival in ALS: a multicenter Italian study.Factors predicting survival in amyotrophic lateral sclerosis patients on non-invasive ventilation.Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement.Procyanidin B2 Protects Neurons from Oxidative, Nitrosative, and Excitotoxic Stress.Current Advances and Limitations in Modeling ALS/FTD in a Dish Using Induced Pluripotent Stem Cells.Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS.Intraspinal Transplantation of the Adipose Tissue-Derived Regenerative Cells in Amyotrophic Lateral Sclerosis in Accordance with the Current Experts' Recommendations: Choosing Optimal Monitoring Tools

P2860

Q21284703-F5A9028F-2371-427E-9D27-9546D00207EB Q24244633-E1B1057F-C961-484E-BBB4-F78C5507B9D5 Q26742196-25356A71-54B3-4688-BE24-F27DBCB12BCD Q28066906-AA8419F4-E899-4138-B18D-F5195DDC85E4 Q28360404-B02A7364-B44B-4D7C-B298-066D55C702C3 Q33761861-D6529DF2-2503-444C-A471-68C19821F2EC Q34554820-2B136C8A-5A75-463A-84D7-5A363CFB8B4C Q35613311-A46989A8-4256-4ADA-A1AE-A66132CA752C Q36555304-AA44FB41-05E8-4872-B4F0-BE2ADDD811DC Q37241079-1DFBDE2E-25F6-487B-80F0-EEA868D9C9E7 Q37712906-DA3B1745-541D-4E1D-9B40-82FA934B7C6E Q38105917-CF135857-70F0-4EBB-8C71-2D2D282F6A73 Q39252157-30B758EB-63D0-4072-A9C4-238461EF9B4E Q39862319-3985520B-1A0A-4869-BDD9-4DCFB65F0FDF Q42369773-2A2298E0-386E-4E30-B2DA-118AFBBA9B53 Q46287091-F5433CFF-5CBF-4A4C-8CDF-4666C64E71A4 Q47868914-F1C6065E-C8C6-433E-AC9B-72F7723DD339 Q50502490-85C1A751-1CCC-4AD5-BAD8-BDF91B968332 Q58787909-E2685E01-7F2A-4542-9900-D8DAEF56EBD1

P2860

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

http://www.wikidata.org/entity/Q33909851

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

2000年论文

@zh

2000年论文

@zh-cn

name

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

@ast

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

@en

Riluzole for amyotrophic lateral sclerosis

@nl

type

label

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

@ast

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

@en

Riluzole for amyotrophic lateral sclerosis

@nl

altLabel

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

@en

prefLabel

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

@ast

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

@en

Riluzole for amyotrophic lateral sclerosis

@nl

P1433

Q33909851-5DDF789F-937C-45A0-B79B-A36F1402906B

P1476

Q33909851-2F276A8E-FFF5-46D9-A2A5-CDB16D12A324

Q33909851-80F2CE40-64FA-483E-9F67-3BE12A6B3842

P2093

Q33909851-193A4460-AB95-458E-895B-ADA88D018179

Q33909851-299CD1CD-1140-4184-A973-8DD83EDDE839

Q33909851-4E3BAF50-05DA-45C0-B35F-D6892953455B

Q33909851-A667A6E1-3AAF-4190-A916-0A8593BCCE57

Q33909851-A92C7093-45CB-4C2E-AFD3-75E8D275D0DB

P2860

Q33909851-6C912720-5BCD-483E-B650-62E1FCA41D65

Q33909851-BA370F75-A841-4954-B833-953B06C96D6E

Q33909851-E8C1C693-9269-44AA-97BC-D611B03D30AA

Q33909851-F01E533E-35E2-4DED-8E82-674EA78C6196

P304

Q33909851-FE2C34DF-3A03-4848-8021-A2FF3D3F3D53

P31

Q33909851-0AB9E169-6300-4EDC-B379-B3BDB0D365C7

P356

Q33909851-BC38BD41-2411-4F05-AF53-95DBCE6E868D

P407

Q33909851-401DAA13-0693-48EE-B439-D3882B47A3FB

P433

Q33909851-1000EDD4-F6A7-4174-9E48-825C1565FE12

Q33909851-7417D734-05A9-4F8F-B75B-F9E35E10F74C

P577

Q33909851-0C78F174-E34E-48EB-A3DE-9E3969DF93A3

Q33909851-0EC04142-A1ED-4326-B1DC-AC0624950A2F

Q33909851-871DECEF-D4D7-4D19-8E1A-24318CD05D4E

P698

Q33909851-DA37243F-6610-4D52-8B51-D8833652D3F1

Q33909851-E665B8A9-36A4-4CFE-A542-7DFC95FB8D41

Q33909851-E847A0F2-CF87-423C-ABD9-5C92FA3C7947

P921

Q33909851-A57EC52A-B191-44ED-B93F-EC1A480A0FC0

P356

14651858.CD001447

P1433

Cochrane Database of Systematic Reviews

P1476

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

@en

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

@en

P2093

D H Moore

http://www.w3.org/2001/XMLSchema#string

J D Mitchell

http://www.w3.org/2001/XMLSchema#string

M Lyon

http://www.w3.org/2001/XMLSchema#string

R G Miller

http://www.w3.org/2001/XMLSchema#string

P2860

Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force.

Clinical trials of riluzole in patients with ALS. ALS/Riluzole Study Group-II.

Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group.

The Riluzole Early Access Programme: descriptive analysis of 844 patients in France. ALS/Riluzole Study Group III.

P304

CD001447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/14651858.CD001447

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

4

http://www.w3.org/2001/XMLSchema#string

P577

2000-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2001-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10796796

http://www.w3.org/2001/XMLSchema#string

11687111

http://www.w3.org/2001/XMLSchema#string

12076411

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis